KRAS mutations, encountered in approximately 20–30% BTC and 90% PDA [34,35,36], confer resistance to anti-EGFR targeting therapies due to downstream constitutive activation of RAS signaling. This evidence concerns the gene KRAS and Patent ductus arteriosus.